Investigators found COVID-19 infection altered the mothers’ immunity at delivery, and gestational COVID-19 exposure alters the immunity of newborns.
Observational studies suggest immune globulin (IG) treatment may reduce the frequency of acute exacerbations of chronic obstructive pulmonary disease (AECOPD).
A new study demonstrates how severe acute respiratory syndrome coronavirus disease 2 (SARS-CoV-2) infection could be associated with an autoimmune response and development of autoantibodies.
Transition of clinic-based to home-based intravenous immune globulin (IVIG)/subcutaneous IG (SCIG) infusion can be successfully done to decrease potential exposure during a pandemic in a high-risk immunosuppressed population.
The National Institutes of Health is conducting a $470 million study to determine why COVID-19 symptoms persist for so long among many patients.
A large multicenter clinical trial has found intravenous immune globulin (IVIG) plus glucocorticoids may be better than IVIG alone for treating multisystem inflammatory syndrome in children (MIS-C) caused by COVID-19.
Kedrion Biopharma is now marketing and distributing RYPLAZIM (plasminogen human-tvmh) in the United States to treat C-PLGD.
The U.S. Food and Drug Administration (FDA) has approved Chemo- Centryx Inc.’s Avacopan, sold under the brand name Tavneos, to treat antineutrophil cytoplasmic antibody-associated vasculitides.
Two recent studies effectively determined the antibody responses of pregnant women infected with SARS-CoV-2 and the effect of the fetal sex on those responses, as well as the direct clinical implications for COVID-19 infection and future maternal-fetal vaccination strategies.
The Centers for Medicare & Medicaid Services (CMS) is making it easier to check COVID-19 vaccination rates for nursing home staff and residents by making vaccination data available in a user-friendly format.
An interim final rule with comment period to further implement the No Surprises Act details a process that will take patients out of the middle of payment disputes, provides a transparent process to settle out-of-network (OON) rates between providers and payers, and outlines requirements for healthcare cost estimates for uninsured (or self-pay) individuals.
The U.S. Department of Health and Human Services (HHS) is making $25.5 billion in new funding available for healthcare providers affected by the COVID- 19 pandemic.
